Reaching Protein Target With SmofKabiven® Extra Nitrogen vs Olimel N9E During the Early Phase of Acute Critical Illness
Status:
Terminated
Trial end date:
2020-03-24
Target enrollment:
Participant gender:
Summary
The main focus of the study is to show that SmofKabiven® extra Nitrogen, in a realistic
clinical setting, enables to meet high protein requirements in patients during the first week
after onset of critical illness, without risk of overfeeding with energy.